UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 460

Sortiert nach

Targeting T cell activation in immuno-oncology

Current oncology (Toronto), 2020-04, Vol.27 (Suppl 2), p.S98-105

2020

Link zum Volltext

Verfügbarkeit prüfen

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)

Annals of oncology, 2023-06, Vol.34 (6), p.520-530

2023

Link zum Volltext

Verfügbarkeit prüfen

Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab

Current oncology (Toronto), 2019-06, Vol.26 (3), p.e418-421

2019

Link zum Volltext

Verfügbarkeit prüfen

Study of TBI-1301 (NY-ESO-1 specific TCR gene transduced autologous T lymphocytes) in patients with solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii441-viii441

2018

Link zum Volltext

Verfügbarkeit prüfen

Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey

Current oncology (Toronto), 2010-08, Vol.17 (4), p.42-47

2010

Link zum Volltext

Verfügbarkeit prüfen

Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells

Biochemical and biophysical research communications, 1999-11, Vol.264 (3), p.781-788

1999

Link zum Volltext

Verfügbarkeit prüfen

1060P Serum metabolomic profiling reveals differences in polyamine and tryptophan metabolites in patients with cutaneous, mucosal and uveal melanoma

Annals of oncology, 2021-09, Vol.32, p.S883-S883

2021

Link zum Volltext

Verfügbarkeit prüfen

2174P The impact of exposure to antibiotic (ATB) and proton pump inhibitor (PPI) therapy on immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study

Annals of oncology, 2023-10, Vol.34, p.S1128-S1128

2023

Link zum Volltext

Verfügbarkeit prüfen

2033MO The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor (ICI) therapy on overall survival (OS): A population-based study

Annals of oncology, 2023-10, Vol.34, p.S1079-S1079

2023

Link zum Volltext

Verfügbarkeit prüfen

1528P A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors

Annals of oncology, 2023-10, Vol.34, p.S860-S860

2023

Link zum Volltext

Verfügbarkeit prüfen

877P Characteristics of malignant cutaneous adnexal tumors in a single-institution study

Annals of oncology, 2022-09, Vol.33, p.S949-S950

2022

Link zum Volltext

Verfügbarkeit prüfen

834P Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO)

Annals of oncology, 2022-09, Vol.33, p.S930

2022

Link zum Volltext

Verfügbarkeit prüfen

778TiP A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors

Annals of oncology, 2022-09, Vol.33, p.S896

2022

Link zum Volltext

Verfügbarkeit prüfen

775P Treatment of Kaposi sarcoma with immune-checkpoint inhibitors: A systematic review and single-arm meta-analysis

Annals of oncology, 2022-09, Vol.33, p.S895

2022

Link zum Volltext

Verfügbarkeit prüfen

1131P Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting

Annals of oncology, 2023-10, Vol.34, p.S679-S679

2023

Link zum Volltext

Verfügbarkeit prüfen

P-31 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors

Annals of oncology, 2023-06, Vol.34, p.S24-S24

2023

Link zum Volltext

Verfügbarkeit prüfen

1687P Targeted metabolomics reveals dynamic changes and potential therapeutic targets in the serum metabolome of patients receiving adoptive cell therapy with tumor infiltrating lymphocytes

Annals of oncology, 2022-09, Vol.33, p.S1312-S1313

2022

Link zum Volltext

Verfügbarkeit prüfen

856P Characterization of patients with brain metastases from metastatic uveal melanoma

Annals of oncology, 2022-09, Vol.33, p.S941

2022

Link zum Volltext

Verfügbarkeit prüfen

989P Autoimmune panels as predictors of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ALERT)

Annals of oncology, 2021-09, Vol.32, p.S844-S845

2021

Link zum Volltext

Verfügbarkeit prüfen

1043P NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma

Annals of oncology, 2021-09, Vol.32, p.S874-S874

2021

Link zum Volltext

Verfügbarkeit prüfen

1144P Clinical predictors of therapeutic benefit from anti-PD1 immune checkpoint inhibitors (ICI) in patients (pts) with metastatic uveal melanoma

Annals of oncology, 2020-09, Vol.31, p.S764-S765

2020

Link zum Volltext

Verfügbarkeit prüfen

531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial

Annals of oncology, 2021-09, Vol.32, p.S596-S596

2021

Link zum Volltext

Verfügbarkeit prüfen

Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours

Annals of oncology, 2019-10, Vol.30, p.v481

2019

Link zum Volltext

Verfügbarkeit prüfen

1183PD - Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours

Annals of oncology, 2019-10, Vol.30, p.v481-v481

2019

Link zum Volltext

Verfügbarkeit prüfen

Weak agonist self‐peptides promote selection and tuning of virus‐specific T cells

European journal of immunology, 2003-03, Vol.33 (3), p.685-696

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 460

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(428)
Mit Volltextzugriff
(390)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(293)
Life Sciences & Biomedicine
(255)
Humans
(152)
Biochemistry & Molecular Biology
(98)
Animals
(83)
Cell Biology
(74)
Male
(69)
Models, Molecular
(65)
Female
(60)
Adult
(52)
Biological And Medical Sciences
(52)
Protein Folding
(49)
Middle Aged
(47)
Cryoelectron Microscopy
(44)
Proteins
(44)
Protein Conformation
(38)
Medical Sciences
(34)
Biophysics
(32)
Multidisciplinary Sciences
(32)
Science & Technology - Other Topics
(32)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Targeting T cell activation in immuno-oncology

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)

Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab

Study of TBI-1301 (NY-ESO-1 specific TCR gene transduced autologous T lymphocytes) in patients with solid tumors

Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey

Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells

1060P Serum metabolomic profiling reveals differences in polyamine and tryptophan metabolites in patients with cutaneous, mucosal and uveal melanoma

2174P The impact of exposure to antibiotic (ATB) and proton pump inhibitor (PPI) therapy on immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study

2033MO The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor (ICI) therapy on overall survival (OS): A population-based study

1528P A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors

877P Characteristics of malignant cutaneous adnexal tumors in a single-institution study

834P Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO)

778TiP A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors

775P Treatment of Kaposi sarcoma with immune-checkpoint inhibitors: A systematic review and single-arm meta-analysis

1131P Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting

P-31 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors

1687P Targeted metabolomics reveals dynamic changes and potential therapeutic targets in the serum metabolome of patients receiving adoptive cell therapy with tumor infiltrating lymphocytes

856P Characterization of patients with brain metastases from metastatic uveal melanoma

989P Autoimmune panels as predictors of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ALERT)

1043P NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma

1144P Clinical predictors of therapeutic benefit from anti-PD1 immune checkpoint inhibitors (ICI) in patients (pts) with metastatic uveal melanoma

531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial

Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours

1183PD - Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours

Weak agonist self‐peptides promote selection and tuning of virus‐specific T cells

Suchergebnisse filtern